DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
The authors evaluated the efficacy of a DHE methanesulphonate for migraine attacks and its tolerability on liver, gallbladder and cardiovascular system functions. Twenty-eight patients affected by migraine were studied. They were withdrawn from preventive therapy for at least one month and treated for three months. The drug showed a good efficacy with a statistical significant reduction of severity and duration of attacks. No variation of the biochemical and morphological parameters of liver, gallbladder and cardiovascular function were found throughout the treatment.
D000293:Adolescent; D000328:Adult; D003692:Delayed-Action Preparations; D004087:Dihydroergotamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy / Q000517:prevention & control*
D003692:Delayed-Action Preparations; D004087:Dihydroergotamine